AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial ...

Daiichi Sankyo has announced the dosage of the first subject in the trial of VANFLYTA in adults with newly diagnosed FLT3-ITD negative AML.

Lisata Therapeutics has completed the enrolment of subjects for the CENDIFOX study of certepetide across multiple cancer types.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

The UK is seeing an overall improvement in its desirability as a clinical trials location, but it still has ground to make up.

While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.

The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated in its first-in-human tests.

Enanta Pharmaceuticals has reported positive topline outcomes from a Phase II trial of zelicapavir for RSV in paediatric patients.